INTRODUCTION: Although amyloid β peptide (Aβ) is cleared from the brain to cerebrospinal fluid and the peripheral circulation, mechanisms for its removal from blood remain unresolved. Primates have uniquely evolved a highly effective peripheral clearance mechanism for pathogens, immune adherence, in which erythrocyte complement receptor 1 (CR1) plays a major role. METHODS: Multidisciplinary methods were used to demonstrate immune adherence capture of Aβ by erythrocytes and its deficiency in Alzheimer's disease (AD). RESULTS: Aβ was shown to be subject to immune adherence at every step in the pathway. Aβ dose-dependently activated serum complement. Complement-opsonized Aβ was captured by erythrocytes via CR1. Erythrocytes, Aβ, and hepatic Kupffer cells were colocalized in the human liver. Significant deficits in erythrocyte Aβ levels were found in AD and mild cognitive impairment patients. DISCUSSION: CR1 polymorphisms elevate AD risk, and >80% of human CR1 is vested in erythrocytes to subserve immune adherence. The present results suggest that this pathway is pathophysiologically relevant in AD.
INTRODUCTION: Although amyloid β peptide (Aβ) is cleared from the brain to cerebrospinal fluid and the peripheral circulation, mechanisms for its removal from blood remain unresolved. Primates have uniquely evolved a highly effective peripheral clearance mechanism for pathogens, immune adherence, in which erythrocyte complement receptor 1 (CR1) plays a major role. METHODS: Multidisciplinary methods were used to demonstrate immune adherence capture of Aβ by erythrocytes and its deficiency in Alzheimer's disease (AD). RESULTS: Aβ was shown to be subject to immune adherence at every step in the pathway. Aβ dose-dependently activated serum complement. Complement-opsonized Aβ was captured by erythrocytes via CR1. Erythrocytes, Aβ, and hepatic Kupffer cells were colocalized in the human liver. Significant deficits in erythrocyte Aβ levels were found in AD and mild cognitive impairmentpatients. DISCUSSION: CR1 polymorphisms elevateAD risk, and >80% of humanCR1 is vested in erythrocytes to subserve immune adherence. The present results suggest that this pathway is pathophysiologically relevant in AD.
Authors: H Zanjani; C E Finch; C Kemper; J Atkinson; D McKeel; J C Morris; J L Price Journal: Alzheimer Dis Assoc Disord Date: 2005 Apr-Jun Impact factor: 2.703
Authors: J B Mackic; M H Weiss; W Miao; E Kirkman; J Ghiso; M Calero; J Bading; B Frangione; B V Zlokovic Journal: J Neurochem Date: 1998-01 Impact factor: 5.372
Authors: Jasmina B Mackic; James Bading; Jorge Ghiso; Larry Walker; Thomas Wisniewski; Blas Frangione; Berislav V Zlokovic Journal: Vascul Pharmacol Date: 2002-06 Impact factor: 5.773
Authors: Brendan T Keenan; Joshua M Shulman; Lori B Chibnik; Towfique Raj; Dong Tran; Mert R Sabuncu; April N Allen; Jason J Corneveaux; John A Hardy; Matthew J Huentelman; Cynthia A Lemere; Amanda J Myers; Anne Nicholson-Weller; Eric M Reiman; Denis A Evans; David A Bennett; Philip L De Jager Journal: Hum Mol Genet Date: 2012-02-17 Impact factor: 6.150
Authors: Jenny U Johansson; William D Brubaker; Harold Javitz; Andrew W Bergen; Denise Nishita; Abhishek Trigunaite; Andrés Crane; Justine Ceballos; Diego Mastroeni; Andrea J Tenner; Marwan Sabbagh; Joseph Rogers Journal: Alzheimers Dement Date: 2018-05-21 Impact factor: 21.566
Authors: Michael X Hernandez; Shan Jiang; Tracy A Cole; Shu-Hui Chu; Maria I Fonseca; Melody J Fang; Lindsay A Hohsfield; Maria D Torres; Kim N Green; Rick A Wetsel; Ali Mortazavi; Andrea J Tenner Journal: Mol Neurodegener Date: 2017-09-18 Impact factor: 14.195
Authors: Rachid Mahmoudi; Sarah Feldman; Aymric Kisserli; Valérie Duret; Thierry Tabary; Laurie-Anne Bertholon; Sarah Badr; Vignon Nonnonhou; Aude Cesar; Antoine Neuraz; Jean Luc Novella; Jacques Henri Max Cohen Journal: Int J Mol Sci Date: 2018-07-25 Impact factor: 5.923